Interestingly, in a longitudinal analysis of a small number of samples, expression of EPHA4 (p = 0.0003) and NPC2 (p = 0.004) correlated significantly with a clinical response to anti-TB treatment [10], suggesting that the full biomarker potential of these genes was not completely investigated in our previous studies [10,11], and that NPC2, EPHA4, and DOCK9 should be further evaluated in order to validate our initial findings. Here, DOCK9 is linked to tuberculosis.